HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Requiring Infant Formula, Medical Food Shortage Updates Included In US FDA Budget Request

Executive Summary

FDA’s justification report published with Biden administration’s FY2022 federal budget request includes $1.194bn for agency’s food programs, which include its oversight of supplement industry, up from $1.11bn in FY2021 appropriation.

You may also be interested in...



US FDA's Dietary Supplement Programs Deserve A Raise, Trade Groups Tell Senate Appropriators

Compliant industry drove US market growth to $55bn in 2020, and faster growth and higher sales are ahead if FDA’s Office of Dietary Supplement Programs has sufficient funding to eliminate non-compliant businesses.

Trump Signs US Appropriations-COVID Relief Bill With Cosmetics, Cannabis, Dietary Provisions

The Consolidated Appropriations Act, H.R. 133, includes $900bn in unemployment relief to COVID victims as well as regular federal appropriations to avoid a looming government shutdown. US FDA provisions include cosmetics and nutrition industry mentions.

In Year Made Unusual By COVID-19, Still More Unusual Consumer Health Claims Surface In US

An ultraviolet lamp marketer was dinged by industry self-regulation for COVID-19 claims; the largest US natural  food grocery chain had one too many undeclared allergens for the FDA's liking; and warnings note cannabidiol-containing eye drops, nasal sprays and inhalers promoted with drug claims.

Related Content

Topics

UsernamePublicRestriction

Register

RS151381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel